A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This study will assess whether daclizumab impairs the ability of children receiving a kidney
transplant to elicit a primary immune response. The anticipated time on study treatment is 1
day, and the target sample size is 82 individuals.